Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Biotechnological Advances in Medicine
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Biotechnological Advances in Medicine

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 18439

Special Issue Editors

Prof. Dr. Marek J. Łos

E-Mail Website
Guest Editor
Centre of Biotechnology, Silesian University of Technology, 44-100 Gliwice, Poland
Interests: cancer immunology; cell death execution pathways; cancer stem cell biology; epigenetic reprogramming (production of iPS-cells); transdifferentiation technologies; other aspects of regenerative pharmacology
Special Issues, Collections and Topics in MDPI journals
Dr. Mohsen Akbari

E-Mail Website
Co-Guest Editor
Laboratory for Innovations in Microengineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V9P 0C8, Canada
Interests: drug delivery; biomaterials; tissue engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The rapid development of experimental biomedical procedures, both at the cellular and tissue level, and in computational biology and data analysis, reflects the progress being achieved in biotechnology and in biomedical sciences in general. With this in mind, we have decided to launch a Special Issue entitled "Biotechnological Advances in Medicine”, which aims to publish high-quality manuscripts pertaining to various aspects of biotechnology, primarily in the area of medicine. Medical biotechnology is a very diverse field. It includes classical laboratory and clinical trial procedures, immunologic and immunogenetic interventions, as well as signal transduction pathway investigations, drug screening, and the development of new biomaterials, bio-inks, and (stem-) cellular procedures for tissue engineering. In the field of medical biotechnology, data analysis, database search and maintenance algorithms, computational modeling of biomedical processes, and automated diagnostic procedures may also involve artificial intelligence. If you are unsure if your manuscript would fit the topic area of the Special Issue, please send the abstract and figures for editorial perusal – presubmission enquiries are strongly encouraged.    

Prof. Dr. Marek J. Łos
Dr. Mohsen Akbari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-small-cell lung cancer
  • lipidomics
  • BCL2L13
  • Anoikis
  • mutation
  • radiation
  • TCR rearrangement
  • glioblastoma
  • nanofibers
  • nanoparticles
  • Hydroxyapatite
  • autophagy
  • medical imaging
  • machine learning
  • leukemia

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

36 pages, 1846 KiB  
Review
Biodegradable and Non-Biodegradable Biomaterials and Their Effect on Cell Differentiation
by Rency Geevarghese, Seyedeh Sara Sajjadi, Andrzej Hudecki, Samad Sajjadi, Nahid Rezvani Jalal, Tayyebeh Madrakian, Mazaher Ahmadi, Małgorzata K. Włodarczyk-Biegun, Saeid Ghavami, Wirginia Likus, Krzysztof Siemianowicz and Marek J. Łos
Int. J. Mol. Sci. 2022, 23(24), 16185; https://doi.org/10.3390/ijms232416185 - 19 Dec 2022
Cited by 32 | Viewed by 5364
Abstract
Biomaterials for tissue scaffolds are key components in modern tissue engineering and regenerative medicine. Targeted reconstructive therapies require a proper choice of biomaterial and an adequate choice of cells to be seeded on it. The introduction of stem cells, and the transdifferentiation procedures, [...] Read more.
Biomaterials for tissue scaffolds are key components in modern tissue engineering and regenerative medicine. Targeted reconstructive therapies require a proper choice of biomaterial and an adequate choice of cells to be seeded on it. The introduction of stem cells, and the transdifferentiation procedures, into regenerative medicine opened a new era and created new challenges for modern biomaterials. They must not only fulfill the mechanical functions of a scaffold for implanted cells and represent the expected mechanical strength of the artificial tissue, but furthermore, they should also assure their survival and, if possible, affect their desired way of differentiation. This paper aims to review how modern biomaterials, including synthetic (i.e., polylactic acid, polyurethane, polyvinyl alcohol, polyethylene terephthalate, ceramics) and natural (i.e., silk fibroin, decellularized scaffolds), both non-biodegradable and biodegradable, could influence (tissue) stem cells fate, regulate and direct their differentiation into desired target somatic cells. Full article
(This article belongs to the Special Issue Biotechnological Advances in Medicine)
►▼ Show Figures

Figure 1

12 pages, 1773 KiB  
Review
Medical Advances in Hepatitis D Therapy: Molecular Targets
by Amelie Vogt, Sabrina Wohlfart, Stephan Urban and Walter Mier
Int. J. Mol. Sci. 2022, 23(18), 10817; https://doi.org/10.3390/ijms231810817 - 16 Sep 2022
Cited by 7 | Viewed by 3707
Abstract
An approximate number of 250 million people worldwide are chronically infected with hepatitis B virus, making them susceptible to a coinfection with hepatitis D virus. The superinfection causes the most severe form of a viral hepatitis and thus drastically worsens the course of [...] Read more.
An approximate number of 250 million people worldwide are chronically infected with hepatitis B virus, making them susceptible to a coinfection with hepatitis D virus. The superinfection causes the most severe form of a viral hepatitis and thus drastically worsens the course of the disease. Until recently, the only available therapy consisted of interferon-α, only eligible for a minority of patients. In July 2020, the EMA granted Hepcludex conditional marketing authorization throughout the European Union. This first-in-class entry inhibitor offers the promise to prevent the spread in order to gain control and eventually participate in curing hepatitis B and D. Hepcludex is an example of how understanding the viral lifecycle can give rise to new therapy options. Sodium taurocholate co-transporting polypeptide, the virus receptor and the target of Hepcludex, and other targets of hepatitis D therapy currently researched are reviewed in this work. Farnesyltransferase inhibitors such as Lonafarnib, targeting another essential molecule in the HDV life cycle, represent a promising target for hepatitis D therapy. Farnesyltransferase attaches a farnesyl (isoprenyl) group to proteins carrying a C-terminal Ca1a2X (C: cysteine, a: aliphatic amino acid, X: C-terminal amino acid) motif like the large hepatitis D virus antigen. This modification enables the interaction of the HBV/HDV particle and the virus envelope proteins. Lonafarnib, which prevents this envelopment, has been tested in clinical trials. Targeting the lifecycle of the hepatitis B virus needs to be considered in hepatitis D therapy in order to cure a patient from both coexisting infections. Nucleic acid polymers target the hepatitis B lifecycle in a manner that is not yet understood. Understanding the possible targets of the hepatitis D virus therapy is inevitable for the improvement and development of a sufficient therapy that HDV patients are desperately in need of. Full article
(This article belongs to the Special Issue Biotechnological Advances in Medicine)
►▼ Show Figures

Graphical abstract

25 pages, 1440 KiB  
Review
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
by Lucia Mazzotti, Anna Gaimari, Sara Bravaccini, Roberta Maltoni, Claudio Cerchione, Manel Juan, Europa Azucena-Gonzalez Navarro, Anna Pasetto, Daniela Nascimento Silva, Valentina Ancarani, Vittorio Sambri, Luana Calabrò, Giovanni Martinelli and Massimiliano Mazza
Int. J. Mol. Sci. 2022, 23(15), 8590; https://doi.org/10.3390/ijms23158590 - 2 Aug 2022
Cited by 20 | Viewed by 8778
Abstract
The immune system is a dynamic feature of each individual and a footprint of our unique internal and external exposures. Indeed, the type and level of exposure to physical and biological agents shape the development and behavior of this complex and diffuse system. [...] Read more.
The immune system is a dynamic feature of each individual and a footprint of our unique internal and external exposures. Indeed, the type and level of exposure to physical and biological agents shape the development and behavior of this complex and diffuse system. Many pathological conditions depend on how our immune system responds or does not respond to a pathogen or a disease or on how the regulation of immunity is altered by the disease itself. T-cells are important players in adaptive immunity and, together with B-cells, define specificity and monitor the internal and external signals that our organism perceives through its specific receptors, TCRs and BCRs, respectively. Today, high-throughput sequencing (HTS) applied to the TCR repertoire has opened a window of opportunity to disclose T-cell repertoire development and behavior down to the clonal level. Although TCR repertoire sequencing is easily accessible today, it is important to deeply understand the available technologies for choosing the best fit for the specific experimental needs and questions. Here, we provide an updated overview of TCR repertoire sequencing strategies, providers and applications to infectious diseases and cancer to guide researchers’ choice through the multitude of available options. The possibility of extending the TCR repertoire to HLA characterization will be of pivotal importance in the near future to understand how specific HLA genes shape T-cell responses in different pathological contexts and will add a level of comprehension that was unthinkable just a few years ago. Full article
(This article belongs to the Special Issue Biotechnological Advances in Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop